- By Katherine Crawford, MS, CGC
- Posted March 10, 2026
The Gene Scene: CALM2
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Caitlin Reid, MS, LGC, CGC
- Posted March 3, 2026
The Gene Scene: RB1
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Brooke Sample, MS, CGC
- Posted February 17, 2026
The Gene Scene: RPE65
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Heather Rocha, MS, CGC
- Posted February 10, 2026
The Gene Scene: LMNA
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Caitlin Reid, MS, LGC, CGC
- Posted February 3, 2026
The Gene Scene: BMPR1A
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Libby Couchon, MS, LCGC
- Posted January 27, 2026
The Gene Scene: KCNH2
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Haley Streff, MS, CGC
- Posted January 20, 2026
The Gene Scene: APOB
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Jessica Scott, MGC, CGC
- Posted January 13, 2026
The Gene Scene: MAX
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Frankie Fann, MS, CGC
- Posted January 6, 2026
The Gene Scene: RUNX1
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Huma Q. Rana, MD, MPH
- Posted December 30, 2025
Study Finds One in Four People With Sarcoma Carry a Pathogenic Variant: Why Germline Testing Matters
I am excited to share results of our large case-control study of 488 people with sarcoma and 2,440 matched cancer-free controls. Our study published in the Journal of the National Cancer Institute (JNCI) sought to determine whether germline pathogenic variants (gPVs) were more frequent in people with sarcoma than in cancer-free controls…